earticle

논문검색

Guideline on the Validation of Viral Clearance for Plasma Derivatives

초록

영어

Human blood is the source of a wide range of medicinal products, especially plasma derivatives, used for the prevention and treatment of diseases. However, the potential for blood-borne viral transmission is still considered to constitute a risk to patients. Viral removal/inactivation processes are introduced to the manufacturing process to assure the viral safety of human
blood plasma products. This guideline pertains to the validation and assessment of the viral removal/inactivation steps. It also provides the checklist for inspection of viral clearance processes.

저자정보

  • Ho Jung Oh Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration,
  • Pan Soon Kim Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration
  • Soon Nam Kim Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration
  • Hye Na Kang Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration
  • Young Lim Kim Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration
  • Naery Lee Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration
  • Kwan Soo Kim Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration,
  • Min Joo Cho Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration,
  • Seung Hwa Hong Blood Products Team, Biologics Headquarters, Korea Food and Drug Administration,

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

      0개의 논문이 장바구니에 담겼습니다.